Kindred Biosciences, Inc., a biopharmaceutical company, focuses on the development of therapies for pets. The company's product pipeline includes small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidates comprise Zimeta, a dipyrone injection for the control of pyrexia (fever) in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. The company's other small molecule product candidates consist of KIND-014 for treatment of equine gastric ulcers in horses; and KIND-015 for the management of clinical signs related to equine metabolic syndrome. It is also developing biologics programs, including KIND-510, a feline recombinant erythropoietin for the control of non-regenerative anemia in cats; KIND-011, an anti-tumor necrosis factor (TNF) to treat newborn foals; and canine atopic dermatitis, an immune-mediated inflammatory, chronic skin disease related to allergies. In addition, the company engages in the development of other biologic product candidates, such as KIND-502 to treat allergic and immune-mediated diseases; KIND-0888, an antibody that targets CD20; various antibodies that target cytokines involved in atopic dermatitis; KIND-509, an antibody that targets the canine TNF; and KIND-Bodies, a biologics scaffold technology. Further, it is developing anti-IL31, anti-IL17, and anti-IL4/13 sink antibodies for treating atopic dermatitis in dogs; anti-TNF antibody for inflammatory bowel disease in dogs; anti-IgE antibody for treating allergic diseases in dogs; anti-VEGF antibody for cancer in dogs; anti-CD20 for treating cancer and autoimmune diseases in dogs; and checkpoint inhibitors to treat cancer in dogs. Kindred Biosciences, Inc. was founded in 2012 and is headquartered in Burlingame, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-701-7901
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.97 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Kindred Biosciences (NASDAQ:KIN) Frequently Asked Questions
What is Kindred Biosciences' stock symbol?
Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."
How were Kindred Biosciences' earnings last quarter?
Kindred Biosciences Inc (NASDAQ:KIN) released its quarterly earnings results on Wednesday, March, 6th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the Zacks' consensus estimate of ($0.42) by $0.04. The biopharmaceutical company had revenue of $1.33 million for the quarter, compared to the consensus estimate of $1.44 million. View Kindred Biosciences' Earnings History.
When is Kindred Biosciences' next earnings date?
What price target have analysts set for KIN?
7 equities research analysts have issued twelve-month price objectives for Kindred Biosciences' stock. Their predictions range from $12.00 to $25.00. On average, they expect Kindred Biosciences' stock price to reach $18.75 in the next twelve months. This suggests a possible upside of 126.7% from the stock's current price. View Analyst Price Targets for Kindred Biosciences.
What is the consensus analysts' recommendation for Kindred Biosciences?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kindred Biosciences.
What are Wall Street analysts saying about Kindred Biosciences stock?
Here are some recent quotes from research analysts about Kindred Biosciences stock:
- 1. HC Wainwright analysts commented, "We maintain our Buy rating of KIN and our 12-month price target of $19.00 per share. We derive our price target based on a risk-adjusted net present value analysis of projected product revenues through 2027 assuming a 10% discount rate and 3% terminal growth rate. We derive an rNPV of $603M for the pipeline products and add in $120M in pro forma cash and cash equivalents to arrive at a 12-month price target of $18.74 per diluted share, which we round to $19.00. Risks: (1) clinical and regulatory; (2) commercial; (3) partnership; (4) financial; and (5) intellectual property." (3/7/2019)
- 2. According to Zacks Investment Research, "Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes. " (3/6/2019)
- 3. Cantor Fitzgerald analysts commented, "We believe KIN’s pipeline of novel animal health drugs will drive long-term shareholder value. As KIN advances its pipeline, we think investors should begin to appreciate the peak revenue potential of the products the company brings to market. Valuation Summary We use a blend of DCF and EV/EBITDA to arrive at our $25 price target. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of DCF and EV/EBITDA to arrive at our $25 price target." (3/5/2019)
Has Kindred Biosciences been receiving favorable news coverage?
News articles about KIN stock have trended somewhat negative on Sunday, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Kindred Biosciences earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term.
Who are some of Kindred Biosciences' key competitors?
Some companies that are related to Kindred Biosciences include Theravance Biopharma (TBPH), Gossamer Bio (GOSS), Corcept Therapeutics (CORT), Aimmune Therapeutics (AIMT), Cambrex (CBM), TherapeuticsMD (TXMD), Phibro Animal Health (PAHC), Apellis Pharmaceuticals (APLS), Esperion Therapeutics (ESPR), Spectrum Pharmaceuticals (SPPI), Epizyme (EPZM), Tricida (TCDA), Homology Medicines (FIXX), Inflarx (IFRX) and Ra Pharmaceuticals (RARX).
What other stocks do shareholders of Kindred Biosciences own?
Who are Kindred Biosciences' key executives?
Kindred Biosciences' management team includes the folowing people:
- Dr. Richard Chin, Co-Founder, CEO & Director (Age 52)
- Ms. Denise M. Bevers, Co-Founder, Pres, COO & Director (Age 52)
- Ms. Wendy K. Wee, Chief Financial Officer (Age 66)
- Dr. Hangjun Zhan, Chief Scientific Officer (Age 59)
- Ms. Katja Buhrer, VP of Corp. Devel. & Investor Relations
Who are Kindred Biosciences' major shareholders?
Kindred Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.44%), Dimensional Fund Advisors LP (4.08%), Dimensional Fund Advisors LP (4.08%), General American Investors Co. Inc. (1.33%), Northern Trust Corp (1.10%) and Geode Capital Management LLC (1.00%). Company insiders that own Kindred Biosciences stock include Park West Asset Management Llc, Raymond Townsend and Richard Chin. View Institutional Ownership Trends for Kindred Biosciences.
Which institutional investors are selling Kindred Biosciences stock?
KIN stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Squarepoint Ops LLC, Bank of America Corp DE, B. Riley Financial Inc., General American Investors Co. Inc., Northern Trust Corp, MetLife Investment Advisors LLC and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have sold Kindred Biosciences company stock in the last year include Raymond Townsend and Richard Chin. View Insider Buying and Selling for Kindred Biosciences.
Which institutional investors are buying Kindred Biosciences stock?
KIN stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Rhumbline Advisers, Granite Investment Partners LLC, BlackRock Inc., Teton Advisors Inc. and Grassi Investment Management. View Insider Buying and Selling for Kindred Biosciences.
How do I buy shares of Kindred Biosciences?
Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kindred Biosciences' stock price today?
One share of KIN stock can currently be purchased for approximately $8.27.
How big of a company is Kindred Biosciences?
Kindred Biosciences has a market capitalization of $321.29 million and generates $1.97 million in revenue each year. The biopharmaceutical company earns $-49,690,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis.
What is Kindred Biosciences' official website?
How can I contact Kindred Biosciences?
Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]
MarketBeat Community Rating for Kindred Biosciences (NASDAQ KIN)
MarketBeat's community ratings are surveys of what our community members think about Kindred Biosciences and other stocks. Vote "Outperform" if you believe KIN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KIN will underperform the S&P 500 over the long term. You may vote once every thirty days.
